Appili Therapeutics Inc.
APLIF
$0.02
-$0.0045-18.37%
| Weiss Ratings | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.40 | |||
| Price History | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -28.83% | |||
| 30-Day Total Return | -21.57% | |||
| 60-Day Total Return | -11.89% | |||
| 90-Day Total Return | -15.25% | |||
| Year to Date Total Return | -19.03% | |||
| 1-Year Total Return | -45.80% | |||
| 2-Year Total Return | -20.95% | |||
| 3-Year Total Return | -78.66% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -46.81% | |||
| 52-Week Low % Change | 48.15% | |||
| Price | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.04 | |||
| 52-Week Low Price | $0.01 | |||
| 52-Week Low Price (Date) | Oct 02, 2024 | |||
| 52-Week High Price (Date) | Apr 04, 2024 | |||
| Valuation | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.54M | |||
| Enterprise Value | 10.30M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.02 | |||
| Earnings Per Share Growth | -26.69% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 28.57 | |||
| Price/Book (Q) | -0.26 | |||
| Enterprise Value/Revenue (TTM) | 115.04 | |||
| Price | $0.02 | |||
| Enterprise Value/EBITDA (TTM) | -1.42 | |||
| Enterprise Value/EBIT | -1.41 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 121.27M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 902 442 4655 | |||
| Address | #21-1344 Summer Street Halifax, NS B3H 0A8 | |||
| Website | appilitherapeutics.com | |||
| Country | Canada | |||
| Year Founded | 2015 | |||
| Profitability | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -8,137.87% | |||
| Profit Margin | -3,236.31% | |||
| Management Effectiveness | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -309.08% | |||
| Return on Equity | -- | |||
| Income Statement | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 89.50K | |||
| Total Revenue (TTM) | 89.50K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | 89.50K | |||
| EBITDA (TTM) | -7.27M | |||
| EBIT (TTM) | -7.28M | |||
| Net Income (TTM) | -2.90M | |||
| Net Income Avl. to Common (TTM) | -2.90M | |||
| Total Revenue Growth (Q YOY) | -77.99% | |||
| Earnings Growth (Q YOY) | -234.46% | |||
| EPS Diluted (TTM) | -0.02 | |||
| EPS Diluted Growth (Q YOY) | -244.44% | |||
| Balance Sheet | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 129.40K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 1.44M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -9.47M | |||
| Current Ratio (Q) | 0.139 | |||
| Book Value Per Share (Q) | -$0.08 | |||
| Total Assets (Q) | 1.46M | |||
| Total Current Liabilities (Q) | 10.36M | |||
| Total Debt (Q) | 7.84M | |||
| Total Liabilities (Q) | 10.93M | |||
| Total Common Equity (Q) | -9.47M | |||
| Cash Flow | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.20K | |||
| Cash from Financing (TTM) | 148.70K | |||
| Net Change in Cash (TTM) | -301.40K | |||
| Levered Free Cash Flow (TTM) | -5.59M | |||
| Cash from Operations (TTM) | -451.30K | |||
